Carboplatin is currently evaluated in numerous clinical trials spanning early- to late-phase development across a broad spectrum of oncological indications, including non-small cell lung cancer, ovarian carcinoma, metastatic breast cancer, head and neck cancer, and metastatic castration-resistant prostate cancer. Sponsored by academic institutions, cooperative research groups, and industry partners, these studies encompass active, recruiting, and completed protocols. Additionally, several clinical trials focus on combination regimens for resectable lung cancer and metastatic breast cancer.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07591467 | NOT_YET_RECRUITING | BRCA-Mutated; Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer; Prostate Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2026-09 | PHASE3 |
| NCT04198766 | RECRUITING | Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer |
Inhibrx Biosciences, Inc |
2019-12-10 | PHASE1; PHASE2 |
| NCT07346196 | NOT_YET_RECRUITING | Squamous Cell Carcinoma |
University of Chicago |
2027-02-07 | PHASE2 |
| NCT07063745 | RECRUITING | Metastatic Non-small Cell Lung Cancer With MTAP Deletion |
Bristol-Myers Squibb |
2026-01-02 | PHASE2; PHASE3 |
| NCT07738315 | NOT_YET_RECRUITING | Endometrial Carcinoma |
Women's Hospital School Of Medicine Zhejiang University |
2026-08-01 | PHASE2 |
| NCT01042379 | RECRUITING | Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer |
QuantumLeap Healthcare Collaborative |
2010-03-01 | PHASE2 |
| NCT07001618 | RECRUITING | NSCLC (Advanced Non-small Cell Lung Cancer) |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-11-17 | PHASE2 |
| NCT05983276 | RECRUITING | Ovarian Cancer |
Loyola University |
2023-11-16 | PHASE2 |
| NCT07709585 | NOT_YET_RECRUITING | Advanced Non-small Cell Lung Cancer (NSCLC); EGFR Exon 19 Deletion Mutation; EGFR Exon 21 Mutation; EGFR Exon 21 L858R Mutation |
Guangzhou University of Traditional Chinese Medicine |
2026-07-05 | PHASE2 |
| NCT06561386 | RECRUITING | Non-small Cell Lung Cancer |
Bristol-Myers Squibb |
2024-10-07 | PHASE3 |
| NCT06990516 | NOT_YET_RECRUITING | Ovarian Cancer |
Tongji Hospital |
2025-06-01 | PHASE1; PHASE2 |
| NCT07290621 | RECRUITING | Oropharyngeal Cancer |
University of Chicago |
2026-02 | PHASE2 |
| NCT06890338 | RECRUITING | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Neoadjuvant |
AbbVie |
2025-11-21 | PHASE2 |
| NCT07739199 | NOT_YET_RECRUITING | Squamous Non-small-cell Lung Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2026-08 | PHASE2; PHASE3 |
| NCT04665206 | RECRUITING | Solid Tumor, Adult; Mesothelioma; NSCLC |
Vivace Therapeutics, Inc |
2021-03-24 | PHASE1; PHASE2 |
| NCT06647563 | NOT_YET_RECRUITING | Squamous Cell Carcinoma of Head and Neck |
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
2024-11-01 | PHASE3 |
| NCT05905315 | RECRUITING | Locally Advanced Vulvar Carcinoma; Squamous Cell Carcinoma of the Vulva |
The Netherlands Cancer Institute |
2024-01-01 | PHASE2 |
| NCT06528496 | RECRUITING | High-risk Neuroblastoma; Neuroblastoma; Childhood Neuroblastoma |
Memorial Sloan Kettering Cancer Center |
2024-07-22 | PHASE2 |
| NCT06953323 | RECRUITING | Advanced Solid Tumor |
Wigen Biomedicine Technology (Shanghai) Co., Ltd. |
2025-07-10 | PHASE1; PHASE2 |
| NCT07276399 | RECRUITING | Squamous Cell Carcinoma of Head and Neck |
Janssen Research & Development, LLC |
2025-12-03 | PHASE3 |
| NCT07129993 | RECRUITING | Urothelial Cancer; Bladder Cancer |
Daiichi Sankyo |
2025-09-26 | PHASE2; PHASE3 |
| NCT06245889 | RECRUITING | Triple Negative Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2024-05-01 | PHASE2 |
| NCT06632327 | ACTIVE_NOT_RECRUITING | Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8 |
Alliance for Clinical Trials in Oncology |
2024-12-11 | PHASE3 |
| NCT06771154 | NOT_YET_RECRUITING | Recurrent/Metastatic Endometrial Cancer |
Peking Union Medical College Hospital |
2025-04-01 | PHASE2 |
| NCT07098988 | RECRUITING | Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor |
CatalYm GmbH |
2025-08-01 | PHASE2 |
| NCT06323369 | RECRUITING | Head and Neck Squamous Cell Carcinoma |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2024-03-25 | PHASE2 |
| NCT07661173 | NOT_YET_RECRUITING | Non Small Cell Lung Cancer |
Anhui Provincial Cancer Hospital |
2026-06-06 | PHASE2 |
| NCT07463313 | NOT_YET_RECRUITING | Thymoma and Thymic Carcinoma |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2026-03 | PHASE2; PHASE3 |
| NCT06996782 | RECRUITING | Advanced or Metastatic Non-small Cell Lung Cancer |
AstraZeneca |
2025-11-24 | PHASE1; PHASE2 |
| NCT07106762 | RECRUITING | Urothelial Cancer |
Bristol-Myers Squibb |
2025-09-30 | PHASE2; PHASE3 |
| NCT07610525 | NOT_YET_RECRUITING | Triple Negative Breast Cancer; Blood and Image Guided; Optimization of Neoadjuvant Therapy; Phase 2 |
M.D. Anderson Cancer Center |
2026-11-05 | PHASE2 |
| NCT06712316 | RECRUITING | Non-small Cell Lung Cancer |
BioNTech SE |
2025-01-07 | PHASE2; PHASE3 |
| NCT07023484 | RECRUITING | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma |
The University of Hong Kong |
2025-05-22 | PHASE2 |
| NCT07622797 | RECRUITING | Late-stage Resectable Esophageal Squamous Carcinoma |
The First Affiliated Hospital of Henan University of Science and Technology |
2025-11-21 | PHASE2 |
| NCT07622186 | RECRUITING | Non-Small Cell Lung Cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
2026-07-15 | PHASE2 |
| NCT07100080 | RECRUITING | Non-Small Cell Lung Cancer |
Bristol-Myers Squibb |
2025-11-05 | PHASE2; PHASE3 |
| NCT05009082 | RECRUITING | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer |
AGO Study Group |
2022-09-13 | PHASE3 |
| NCT07028281 | RECRUITING | Malignant Solid Tumors |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
2025-07-08 | PHASE2 |
| NCT06535607 | RECRUITING | Sub-study 1 Cervical Cancer (Volrustomig Monotherapy); Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy); Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy); Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy); Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy) |
AstraZeneca |
2024-08-22 | PHASE2 |
| NCT07181499 | RECRUITING | NSCLC; Adjuvant Drug Therapy; EGFR |
Betta Pharmaceuticals Co., Ltd. |
2025-09 | PHASE2 |
| NCT07213804 | RECRUITING | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-10-22 | PHASE3 |
| NCT07016399 | RECRUITING | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma |
Vandana Abramson |
2025-09-09 | PHASE2 |
| NCT06699212 | RECRUITING | Recurrent Head and Neck Squamous Cell Carcinoma |
Rakuten Medical, Inc. |
2024-12-24 | PHASE3 |
| NCT06393816 | RECRUITING | Large Cell Neuroendocrine Carcinoma of the Lung |
Centre Leon Berard |
2024-06-13 | PHASE2 |
| NCT06663098 | RECRUITING | Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
Gruppo Oncologico Italiano di Ricerca Clinica |
2025-01-24 | PHASE2 |
| NCT06204614 | ENROLLING_BY_INVITATION | Muscle Invasive Bladder Urothelial Carcinoma |
Brigham and Women's Hospital |
2024-06-14 | EARLY_PHASE1 |
| NCT07559929 | NOT_YET_RECRUITING | Small Cell Lung Cancer |
Hangzhou DAC Biotechnology Co., Ltd. |
2026-06-01 | PHASE1; PHASE2 |
| NCT04811703 | RECRUITING | Metastatic Ovarian Carcinoma; Peritoneal Carcinomatosis; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Stage III Fallopian Tube Cancer; Stage IV Fallopian Tube Cancer; Metastatic Malignant Neoplasm in the Peritoneum |
Hospices Civils de Lyon |
2021-07-30 | PHASE1 |
| NCT05502237 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Gilead Sciences |
2022-10-12 | PHASE3 |
| NCT06084845 | WITHDRAWN | Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 |
ECOG-ACRIN Cancer Research Group |
2024-04-12 | PHASE2 |
| NCT05472220 | WITHDRAWN | Solid Tumors, Adult; PIK3CA Mutation-Related Tumors; PIK3CA Mutation; Human Papillomavirus-Related Carcinoma; HPV-Related Squamous Cell Carcinoma; Human Papillomavirus-Related Squamous Cell Carcinoma; Locally Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm |
Pamela Munster |
2022-11-01 | PHASE1 |
| NCT07383116 | NOT_YET_RECRUITING | Non Squamous Non-small Cell Lung Cancer |
Shanghai Huaota Biopharmaceutical Co., Ltd. |
2026-01-15 | PHASE3 |
| NCT06926868 | RECRUITING | Breast Neoplasms |
Bristol-Myers Squibb |
2025-09-11 | PHASE2; PHASE3 |
| NCT05684276 | ACTIVE_NOT_RECRUITING | NSCLC; Pancoast Tumor |
Fundación GECP |
2023-05-12 | PHASE2 |
| NCT05902169 | RECRUITING | Glioblastoma; Recurrent Glioblastoma; GBM |
CarThera |
2024-01-29 | PHASE3 |
| NCT06771622 | ACTIVE_NOT_RECRUITING | Solid Cancer |
FBD Biologics Limited |
2025-03-13 | PHASE1; PHASE2 |
| NCT06464068 | RECRUITING | Extrapulmonary Small Cell Carcinoma |
Gruppo Oncologico Italiano di Ricerca Clinica |
2024-01-16 | PHASE2 |
| NCT01154920 | ACTIVE_NOT_RECRUITING | Head and Neck Squamous Cell Carcinoma |
M.D. Anderson Cancer Center |
2010-07-09 | PHASE2 |
| NCT07244978 | NOT_YET_RECRUITING | Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapy |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-06-01 | PHASE2 |
| NCT07401654 | NOT_YET_RECRUITING | Ovarian Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2026-01-31 | PHASE2 |
| NCT02726997 | ACTIVE_NOT_RECRUITING | Stage III Fallopian Tube Cancer AJCC v7; Stage III Ovarian Cancer AJCC v6 and v7; Stage III Primary Peritoneal Cancer AJCC v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7 |
M.D. Anderson Cancer Center |
2016-07-06 | PHASE1; PHASE2 |
| NCT07761429 | RECRUITING | Cancer of Unknown Primary Site |
Shandong New Time Pharmaceutical Co., LTD |
2026-07-08 | PHASE2; PHASE3 |
| NCT07311577 | RECRUITING | Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent |
Jiangsu Cancer Institute & Hospital |
2026-01-01 | PHASE2 |
| NCT07172412 | NOT_YET_RECRUITING | Extensive Stage Lung Small Cell Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2025-11 | PHASE2 |
| NCT05652686 | RECRUITING | Small Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC); Neuroendocrine Carcinomas (NEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) |
Phanes Therapeutics |
2023-09-05 | PHASE1; PHASE2 |
| NCT07220135 | RECRUITING | Breast Cancer |
University of Kansas Medical Center |
2025-11-14 | PHASE2 |
| NCT07241767 | RECRUITING | Lung Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2025-11-12 | PHASE2 |
| NCT05599984 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors |
AbbVie |
2022-12-05 | PHASE1 |
| NCT05256225 | RECRUITING | Endometrial Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor |
National Cancer Institute (NCI) |
2022-11-16 | PHASE3 |
| NCT07009457 | ACTIVE_NOT_RECRUITING | Widespread Small Cell Lung Cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
2025-06-16 | PHASE1 |
| NCT05487391 | RECRUITING | Carcinoma, Non-Small-Cell Lung |
Qilu Pharmaceutical Co., Ltd. |
2022-12-08 | PHASE3 |
| NCT07061535 | RECRUITING | Extensive-stage Small Cell Lung Cancer (ES-SCLC); Extensive Stage Lung Small Cell Cancer; Extensive-Stage Small-Cell Lung Cancer; Extensive Disease Small Cell Lung Cancer |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2025-07-30 | PHASE2 |
| NCT06057038 | ACTIVE_NOT_RECRUITING | Malignant Solid Tumor |
Genmab |
2023-11-24 | PHASE1 |
| NCT05198830 | ACTIVE_NOT_RECRUITING | Lung Adenocarcinoma; Lung Large Cell Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2022-12-15 | PHASE2 |
| NCT07137858 | NOT_YET_RECRUITING | Oral Squamous Cell Carcinoma (OSCC); Neoadjuvant Chemoimmunotherapy |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2025-08-15 | PHASE2 |
| NCT05420454 | RECRUITING | Breast Cancer |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2022-07-10 | PHASE4 |
| NCT04999761 | RECRUITING | Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Alveolar Soft Part Sarcoma; Esophageal Cancer; Head and Neck Cancer; Biliary Tract Cancer |
Taiho Pharmaceutical Co., Ltd. |
2021-06-01 | PHASE1 |
| NCT02341989 | ACTIVE_NOT_RECRUITING | Testicular Neoplasms; Seminoma |
St. Olavs Hospital |
2015-04-08 | PHASE3 |
| NCT02297217 | RECRUITING | Esophageal Cancer |
AHS Cancer Control Alberta |
2019-11-21 | PHASE2 |
| NCT06375109 | NOT_YET_RECRUITING | Limited-stage Small-cell Lung Cancer |
Beijing Chest Hospital, Capital Medical University |
2024-04-16 | PHASE2 |
| NCT06407310 | NOT_YET_RECRUITING | Triple Negative Breast Cancer |
Tel Aviv Medical Center |
2024-07-01 | PHASE2 |
| NCT07059221 | RECRUITING | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
2025-07-11 | PHASE1; PHASE2 |
| NCT06727565 | ACTIVE_NOT_RECRUITING | Head and Neck Squamous Cell Carcinoma |
Gilead Sciences |
2025-02-18 | PHASE2 |
| NCT07493980 | NOT_YET_RECRUITING | NSCLC Stage II |
Shanghai Pulmonary Hospital, Shanghai, China |
2026-03 | PHASE2 |
| NCT04460352 | RECRUITING | Esophageal Squamous Cell Carcinoma |
Karolinska University Hospital |
2020-11-27 | PHASE3 |
| NCT02955082 | ACTIVE_NOT_RECRUITING | Hormone Refractory Prostate Cancer |
Institute of Cancer Research, United Kingdom |
2017-05-25 | PHASE2 |
| NCT06751277 | NOT_YET_RECRUITING | Recurrent or Metastatic Endometrial Cancer |
xiang yang |
2025-02-01 | PHASE2 |
| NCT06157827 | RECRUITING | Advanced Neuroendocrine Carcinoma |
Nanjing Leads Biolabs Co.,Ltd |
2023-12-08 | PHASE1; PHASE2 |
| NCT06652048 | RECRUITING | Non-Small Cell Lung Cancer |
Jialei Wang |
2024-10-01 | PHASE2 |
| NCT07136285 | RECRUITING | SCLC, Extensive Stage |
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. |
2023-07-24 | PHASE1; PHASE2 |
| NCT06943820 | RECRUITING | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal Adenocarcinoma; Advanced Solid Tumors |
Akeso |
2025-05-21 | PHASE1; PHASE2 |
| NCT06704620 | NOT_YET_RECRUITING | Advanced and Metastatic NSCLC |
Tianjin Medical University Cancer Institute and Hospital |
2024-12 | PHASE3 |
| NCT02962063 | ACTIVE_NOT_RECRUITING | Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma |
Memorial Sloan Kettering Cancer Center |
2016-11 | PHASE1; PHASE2 |
| NCT04162015 | ACTIVE_NOT_RECRUITING | Malignant Pleural Mesothelioma |
Memorial Sloan Kettering Cancer Center |
2019-11-12 | PHASE1 |
| NCT04129502 | ACTIVE_NOT_RECRUITING | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Takeda |
2020-01-10 | PHASE3 |
| NCT06303713 | ACTIVE_NOT_RECRUITING | Prostate Cancer; Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer |
Dana-Farber Cancer Institute |
2024-05-22 | PHASE1 |
| NCT06447662 | ACTIVE_NOT_RECRUITING | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-06-27 | PHASE1 |
| NCT06362252 | RECRUITING | Extensive Stage-small Cell Lung Cancer |
Daiichi Sankyo |
2024-07-22 | PHASE1; PHASE2 |
| NCT05116462 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Innovent Biologics (Suzhou) Co. Ltd. |
2024-03-15 | PHASE3 |
| NCT05186974 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Gilead Sciences |
2022-05-30 | PHASE2 |
| NCT07125391 | RECRUITING | Ovarian Cancer |
Bai-Rong Xia |
2025-06-20 | PHASE2 |
| NCT04339218 | RECRUITING | Lung Adenocarcinoma; Cryotherapy Effect |
Institut Bergonié |
2020-08-28 | PHASE3 |
| NCT04966663 | RECRUITING | Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA |
University Health Network, Toronto |
2022-03-28 | PHASE2 |
| NCT05351788 | RECRUITING | Non-small Cell Lung Cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
2022-05-20 | PHASE2 |
| NCT04304248 | UNKNOWN | Non Small Cell Lung Cancer |
Hao Long |
2019-08-01 | PHASE2 |
| NCT06911606 | RECRUITING | SCLC, Limited Stage |
Guangdong Provincial People's Hospital |
2024-05-22 | PHASE2 |
| NCT05298423 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Merck Sharp & Dohme LLC |
2022-05-03 | PHASE3 |
| NCT04862650 | ACTIVE_NOT_RECRUITING | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Hypopharyngeal Squamous Cell Carcinoma; Metastatic Laryngeal Squamous Cell Carcinoma; Metastatic Oral Cavity Squamous Cell Carcinoma; Metastatic Oropharyngeal Squamous Cell Carcinoma; Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Recurrent Head and Neck Squamous Cell Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Oral Cavity Squamous Cell Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVC Hypopharyngeal Carcinoma AJCC v8; Stage IVC Laryngeal Cancer AJCC v8; Stage IVC Lip and Oral Cavity Cancer AJCC v8 |
Marcelo Bonomi |
2021-11-30 | PHASE2 |
| NCT04015778 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2019-08-08 | PHASE2 |
| NCT07365410 | NOT_YET_RECRUITING | Non-small Cell Lung Cancer (NSCLC); Brain Metastases; Furmonertinib; EGFR Mutation |
Tianjin Medical University Cancer Institute and Hospital |
2026-01 | PHASE2 |
| NCT06980545 | NOT_YET_RECRUITING | Stage III and IV Ovarian Cancer |
Assiut University |
2025-06-30 | PHASE3 |
| NCT06897579 | TERMINATED | Extensive Stage Small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2025-04-07 | PHASE2 |
| NCT04638582 | TERMINATED | Lung Cancer, Nonsmall Cell |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2022-08-28 | PHASE2 |
| NCT05743270 | WITHDRAWN | Squamous Cell Carcinoma of Head and Neck; Locally Advanced Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma |
Replimune, Inc. |
2024-01-30 | PHASE2 |
| NCT05117476 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumor; NSCLC |
Cullinan Therapeutics Inc. |
2021-10-29 | PHASE1 |
| NCT05468489 | ACTIVE_NOT_RECRUITING | Extensive Stage Small Cell Lung Cancer |
Shanghai Henlius Biotech |
2022-11-18 | PHASE3 |
| NCT04147351 | COMPLETED | NSCLC Stage IIIB~IV |
National Taiwan University Hospital |
2020-04-10 | PHASE2 |
| NCT05501665 | RECRUITING | Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage III Lung Cancer |
Vanderbilt-Ingram Cancer Center |
2023-05-09 | PHASE1; PHASE2 |
| NCT03781986 | ACTIVE_NOT_RECRUITING | Malignant Salivary Gland Cancer; Salivary Gland Cancer |
University of Michigan Rogel Cancer Center |
2019-10-28 | PHASE1; PHASE2 |
| NCT05668988 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Dizal Pharmaceuticals |
2022-12-13 | PHASE3 |
| NCT03203590 | UNKNOWN | 2-year Disease-Free Survival |
Sun Yat-sen University |
2017-09 | PHASE3 |
| NCT03919552 | RECRUITING | Cisplatin; Carboplatin; NPC |
Nanfang Hospital, Southern Medical University |
2018-01-31 | PHASE3 |
| NCT03623776 | WITHDRAWN | Efficacy and Safety |
Sun Yat-sen University |
2019-02-01 | PHASE2 |
| NCT03582475 | ACTIVE_NOT_RECRUITING | Bladder Small Cell Neuroendocrine Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Prostate Carcinoma Metastatic in the Bone; Prostate Neuroendocrine Neoplasm; Prostate Small Cell Carcinoma; Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8; Stage III Prostate Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Ureter Small Cell Carcinoma; Urothelial Carcinoma |
Jonsson Comprehensive Cancer Center |
2019-01-11 | PHASE1 |
| NCT06659042 | RECRUITING | Lung Cancer, Non-Small Cell |
Shanghai Chest Hospital |
2024-11-20 | PHASE2 |
| NCT06164327 | UNKNOWN | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
BeBetter Med Inc |
2023-12-01 | PHASE1 |
| NCT04649385 | COMPLETED | Advanced Solid Tumor |
BeiGene |
2021-03-04 | PHASE1 |
| NCT03036488 | COMPLETED | Triple Negative Breast Neoplasms |
Merck Sharp & Dohme LLC |
2017-03-07 | PHASE3 |
| NCT03520686 | TERMINATED | Non Small Cell Lung Cancer |
ImmunityBio, Inc. |
2018-05-18 | PHASE3 |
| NCT06574763 | UNKNOWN | Ovarian Cancer |
Sun Yat-sen University |
2024-09-01 | PHASE2 |
| NCT05374512 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2022-05-16 | PHASE3 |
| NCT05930665 | UNKNOWN | Pleural Mesothelioma |
Sun Yat-sen University |
2023-11-01 | PHASE2 |
| NCT03918278 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2019-06-19 | PHASE1 |
| NCT04046575 | ACTIVE_NOT_RECRUITING | Esophagus Cancer; Esophageal Cancer; Cancer of the Esophagus |
Washington University School of Medicine |
2019-11-07 | PHASE1 |
| NCT02520154 | COMPLETED | Stage III Fallopian Tube Cancer AJCC v7; Stage III Ovarian Cancer AJCC v6 and v7; Stage III Primary Peritoneal Cancer AJCC v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7 |
M.D. Anderson Cancer Center |
2016-07-05 | PHASE2 |
| NCT02429687 | RECRUITING | Ovarian Germ Cell Cancer; Ovarian Neoplasms; Ovarian Cancer |
Beihua Kong |
2015-04 | PHASE3 |
| NCT03088540 | COMPLETED | Carcinoma，Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsmall Cell Lung Cancer |
Regeneron Pharmaceuticals |
2017-05-29 | PHASE3 |
| NCT06396065 | ACTIVE_NOT_RECRUITING | Non-Squamous Non-small Cell Lung Cancer |
Summit Therapeutics |
2023-05-04 | PHASE3 |
| NCT06087289 | COMPLETED | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer |
Novakand Pharma AB |
2023-04-26 | PHASE1; PHASE2 |
| NCT04832854 | TERMINATED | Non-Small Cell Lung Cancer (NSCLC) |
Hoffmann-La Roche |
2021-04-23 | PHASE2 |
| NCT04222972 | TERMINATED | RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue |
Hoffmann-La Roche |
2020-07-24 | PHASE3 |
| NCT06355024 | COMPLETED | Triple-negative Breast Cancer |
Fudan University |
2024-05-11 | PHASE2 |
| NCT04617756 | RECRUITING | Urothelial Carcinoma; Cancer |
Centre Hospitalier Universitaire de Nīmes |
2021-09-29 | PHASE2 |
| NCT04547907 | RECRUITING | Breast Cancer,HER2-positive |
Henan Cancer Hospital |
2020-09-18 | PHASE3 |
| NCT05312840 | COMPLETED | Non Small Cell Lung Cancer |
People's Hospital of Quzhou |
2022-01-01 | PHASE4 |
| NCT04856176 | TERMINATED | Advanced Lung Non-Small Cell Carcinoma; Non-Small Cell Carcinoma of Lung, TNM Stage 4 |
Tufts Medical Center |
2022-01-03 | PHASE2 |
| NCT06016413 | NOT_YET_RECRUITING | Head and Neck Squamous Cell Carcinoma |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2023-09-01 | PHASE2 |
| NCT06237257 | UNKNOWN | Locally Advanced Cervical Cancer |
Shanghai Shengdi Pharmaceutical Co., Ltd |
2024-03-20 | PHASE2 |
| NCT01706120 | UNKNOWN | Ovarian Cancer |
National Cancer Institute, Naples |
2012-10 | PHASE4 |
| NCT02794571 | COMPLETED | Advanced/Metastatic Tumors |
Genentech, Inc. |
2016-05-23 | PHASE1 |
| NCT05900921 | UNKNOWN | Advanced Squamous Non-Small-Cell Lung Cancer |
Sichuan University |
2023-07-01 | PHASE2 |
| NCT02584478 | UNKNOWN | Endometrial Carcinoma; Ovarian Carcinoma; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Cervical Carcinoma |
Advenchen Laboratories, LLC |
2015-12 | PHASE3 |
| NCT01149083 | COMPLETED | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Unresectable Breast Carcinoma |
National Cancer Institute (NCI) |
2010-06-30 | PHASE2 |
| NCT05756972 | ACTIVE_NOT_RECRUITING | NSCLC |
Biotheus Inc. |
2023-06-26 | PHASE2 |
| NCT05543629 | TERMINATED | Advanced Solid Tumors; Non-small Cell Lung Cancer |
Bristol-Myers Squibb |
2022-10-04 | PHASE1; PHASE2 |
| NCT03107182 | COMPLETED | HPV-Related Squamous Cell Carcinoma; HNSCC |
University of Chicago |
2017-06-27 | PHASE2 |
| NCT06094296 | TERMINATED | NSCLC |
Bristol-Myers Squibb |
2023-11-27 | PHASE2 |
| NCT05715840 | UNKNOWN | Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2023-01-31 | PHASE3 |
| NCT03393884 | ACTIVE_NOT_RECRUITING | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer |
Imunon |
2018-09-05 | PHASE1; PHASE2 |
| NCT02964013 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2016-12-13 | PHASE1 |
| NCT03850067 | COMPLETED | Small Cell Lung Carcinoma |
Celgene |
2019-03-12 | PHASE1 |
| NCT04269200 | ACTIVE_NOT_RECRUITING | Endometrial Neoplasms |
AstraZeneca |
2020-05-05 | PHASE3 |
| NCT03390686 | ACTIVE_NOT_RECRUITING | Lung Cancer; Non-small Cell Lung Cancer |
Prestige Biopharma Limited |
2019-11-15 | PHASE3 |
| NCT05132985 | NOT_YET_RECRUITING | NSCLC; EGF-R Positive Non-Small Cell Lung Cancer |
Liaoning Cancer Hospital & Institute |
2022-01-01 | PHASE2 |
| NCT04967417 | COMPLETED | Non-small Cell Lung Cancer |
Samsung Medical Center |
2022-05-26 | PHASE2 |
| NCT03574779 | COMPLETED | Ovarian Neoplasms |
Tesaro, Inc. |
2018-11-15 | PHASE2 |
| NCT05572476 | WITHDRAWN | Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma; Extensive-stage Small-cell Lung Cancer |
Institut Bergonié |
2023-10 | PHASE2 |
| NCT04799249 | COMPLETED | TNBC - Triple-Negative Breast Cancer; Breast Cancer |
G1 Therapeutics, Inc. |
2021-05-14 | PHASE3 |
| NCT04063163 | COMPLETED | Extensive Stage Small Cell Lung Cancer |
Shanghai Henlius Biotech |
2019-09-12 | PHASE3 |
| NCT06393816 | Not yet recruiting | Large Cell Neuroendocrine Carcinoma of the Lung |
Centre Leon Berard|Groupe Français de Pneumo-Cancérologie |
2024-05 | Phase 2 |
| NCT06303713 | Not yet recruiting | Prostate Cancer|Metastatic Prostate Cancer|Metastatic Castration-resistant Prostate Cancer |
Dana-Farber Cancer Institute|Novartis |
2024-05 | Phase 1 |
| NCT05846789 | Recruiting | Metastatic Breast Cancer|Triple Negative Breast Cancer|Estrogen-receptor-low Breast Cancer |
Kathy Miller|Genentech Inc.|Indiana University |
2024-05 | Phase 2 |
| NCT04619797 | COMPLETED | Non-small Cell Lung Cancer (NSCLC) |
Hoffmann-La Roche |
2020-12-15 | PHASE2; PHASE3 |
| NCT04526691 | ACTIVE_NOT_RECRUITING | Advanced or Metastatic NSCLC |
Daiichi Sankyo |
2020-09-15 | PHASE1 |
| NCT05298176 | COMPLETED | Non-Small Cell Lung Cancer |
Amsterdam UMC, location VUmc |
2022-01-04 | PHASE2 |
| NCT06288854 | Not yet recruiting | Weight Gain |
Rajavithi Hospital |
2024-04-03 | Not Applicable |
| NCT05872412 | UNKNOWN | Triple Negative Breast Cancer |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2023-06-01 | PHASE2 |
| NCT05367206 | RECRUITING | Cervical Cancer; Neoadjuvant Chemotherapy; Bulky Neoplasm |
Sun Yat-sen University |
2022-03-14 | PHASE3 |
| NCT04524689 | TERMINATED | Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) |
Sanofi |
2020-10-26 | PHASE2 |
| NCT05611879 | UNKNOWN | NSCLC, Stage III |
Beijing Tsinghua Chang Gung Hospital |
2023-03-12 | PHASE2 |
| NCT04868708 | COMPLETED | Recurrent or Metastatic Cervical Cancer |
Akeso |
2021-04-01 | PHASE2 |
| NCT01847326 | COMPLETED | Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Tongue Cancer |
University of Chicago |
2013-03-26 | PHASE1 |
| NCT04951115 | TERMINATED | Small-cell Lung Cancer |
Weill Medical College of Cornell University |
2021-07-12 | PHASE2 |
| NCT05386888 | COMPLETED | NSCLC, Stage III |
Genfleet Therapeutics (Shanghai) Inc. |
2022-09-09 | PHASE2 |
| NCT00980954 | COMPLETED | Cervical Cancer |
Radiation Therapy Oncology Group |
2009-09 | PHASE3 |
| NCT05151549 | UNKNOWN | Cervical Cancer |
Hunan Cancer Hospital |
2021-12-01 | PHASE2 |
| NCT00657878 | UNKNOWN | Ovarian Cancer |
National Cancer Institute, Naples |
2008-11 | PHASE3 |
| NCT04440358 | COMPLETED | Recurrent Glioblastoma |
InSightec |
2020-10-13 | PHASE1; PHASE2 |
| NCT04871529 | TERMINATED | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8 |
SWOG Cancer Research Network |
2022-08-10 | PHASE2 |
| NCT02501954 | COMPLETED | Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer |
Women's Cancer Care Associates, LLC |
2015-03 | PHASE3 |
| NCT02436993 | ACTIVE_NOT_RECRUITING | Breast Carcinoma |
University of California, Irvine |
2015-04 | PHASE2 |
| NCT04865289 | COMPLETED | Endometrial Neoplasms |
Merck Sharp & Dohme LLC |
2019-10-22 | PHASE3 |
| NCT04981899 | UNKNOWN | Hodgkin Lymphoma |
St. Petersburg State Pavlov Medical University |
2021-03-01 | PHASE1; PHASE2 |
| NCT03976362 | COMPLETED | Carcinoma, Squamous Cell, Non-small-cell Lung |
Merck Sharp & Dohme LLC |
2019-06-28 | PHASE3 |
| NCT04923776 | TERMINATED | Small-cell Lung Cancer |
Brian Henick, MD |
2021-09-20 | PHASE2 |
| NCT05030077 | UNKNOWN | Urothelial Carcinoma; Anlotinib; Urogenital Neoplasms; Cisplatin; Carboplatin; Gemcitabine; Antineoplastic Agents |
Tianjin Medical University Second Hospital |
2021-10-01 | PHASE2 |
| NCT04238988 | UNKNOWN | Locally Advanced Cervical Cancer |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2021-02-18 | PHASE2 |
| NCT04870112 | TERMINATED | Non-Small Cell Lung Cancer; Small Cell Lung Cancer |
AstraZeneca |
2021-06-28 | PHASE1 |
| NCT04028050 | COMPLETED | Small Cell Lung Carcinoma |
Hoffmann-La Roche |
2019-08-12 | PHASE3 |
| NCT03141359 | ACTIVE_NOT_RECRUITING | Lung Cancer Stage II; Lung Cancer Stage III; Non Small Cell Lung Cancer |
Wake Forest University Health Sciences |
2017-05-12 | PHASE2 |
| NCT04770272 | TERMINATED | Triple-negative Breast Cancer |
Palleos Healthcare GmbH |
2021-03-01 | PHASE2 |
| NCT04712903 | COMPLETED | Small Cell Lung Carcinoma Extensive Disease |
AstraZeneca |
2020-12-16 | PHASE3 |
| NCT04840290 | UNKNOWN | Non Small Cell Lung Cancer |
Tang-Du Hospital |
2019-06-01 | PHASE3 |
| NCT03289910 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Atypical Chronic Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis; Polycythemia Vera; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2018-09-24 | PHASE2 |
| NCT04005716 | COMPLETED | Small Cell Lung Cancer |
BeiGene |
2019-07-22 | PHASE3 |
| NCT04815408 | UNKNOWN | Ovarian Cancer; Neoadjuvant Chemotherapy; Anti-PD-1; Neoadjuvant Immunotherapy |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2021-04-01 | PHASE2 |
| NCT04846634 | NOT_YET_RECRUITING | Resectable Locally Advanced Non-small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-08 | PHASE2 |
| NCT03515837 | COMPLETED | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2018-06-29 | PHASE3 |
| NCT04722718 | UNKNOWN | Breast Cancer |
Jiuda Zhao |
2021-02-01 | PHASE2 |
| NCT05207904 | UNKNOWN | Non-Small Cell Squamous Lung Cancer; Brain Metastases |
Sun Yat-sen University |
2021-06-17 | PHASE2 |
| NCT05318443 | COMPLETED | Non-squamous Non-small-cell Lung Cancer |
Shanghai Institute Of Biological Products |
2020-04-17 | PHASE3 |
| NCT02629718 | UNKNOWN | PFS; OS; Quality of Life |
Sun Yat-sen University |
2015-12 | PHASE3 |
| NCT03206203 | COMPLETED | Triple Negative Breast Cancer; Stage IV Breast Cancer; HER2 Negative; Invasive Breast Cancer |
Vanderbilt-Ingram Cancer Center |
2017-08-29 | PHASE2 |
| NCT04422392 | TERMINATED | Non Small Cell Lung Cancer |
Shanghai Pulmonary Hospital, Shanghai, China |
2020-07-13 | PHASE2 |
| NCT03965689 | ACTIVE_NOT_RECRUITING | Metastatic Lung Non-Small Cell Squamous Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Lung Non-Squamous Non-Small Cell Carcinoma |
National Cancer Institute (NCI) |
2020-04-16 | PHASE2 |
| NCT04861948 | TERMINATED | Solid Tumors; Lung Adenocarcinoma; Osteosarcoma |
Innovent Biologics (Suzhou) Co. Ltd. |
2021-05-25 | PHASE1 |
| NCT04022876 | TERMINATED | Non Small Cell Lung Cancer; Small-cell Lung Cancer |
Aileron Therapeutics, Inc. |
2019-09-03 | PHASE1 |
| NCT03992911 | UNKNOWN | Neuroendocrine Carcinoma of the Bladder |
Peking University |
2019-06-19 | PHASE2; PHASE3 |
| NCT04551950 | COMPLETED | Cervical Cancer |
EMD Serono Research & Development Institute, Inc. |
2020-10-19 | PHASE1 |
| NCT04825938 | NOT_YET_RECRUITING | Salivary Gland Malignant Neoplasms; Salivary Gland Tumors |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-04-30 | PHASE2 |
| NCT03717415 | TERMINATED | Locally Advanced or Metastatic Solid Tumor |
Deciphera Pharmaceuticals, LLC |
2019-01-02 | PHASE1; PHASE2 |
| NCT04405674 | UNKNOWN | Non Small Cell Lung Cancer |
Shanghai Chest Hospital |
2020-07-15 | PHASE2 |
| NCT03674242 | TERMINATED | Triple Negative Breast Cancer |
ERYtech Pharma |
2019-06-13 | PHASE2; PHASE3 |
| NCT04203485 | UNKNOWN | PD-L1 Positive Non-small Cell Lung Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2020-06-15 | PHASE3 |
| NCT03737123 | TERMINATED | Urothelial Carcinoma |
Nabil Adra |
2018-12-19 | PHASE2 |
| NCT04632342 | UNKNOWN | Radiation Pneumonitis; Lung Cancer |
Hanlim Pharm. Co., Ltd. |
2020-11 | PHASE2 |
| NCT04470076 | UNKNOWN | Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2020-07-10 | PHASE2 |
| NCT04902885 | COMPLETED | Extensive-stage Small-cell Lung Cancer |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2021-05-25 | PHASE3 |
| NCT03713944 | TERMINATED | NSCLC Stage IV; NSCLC, Recurrent |
Nasser Hanna |
2018-11-15 | PHASE2 |
| NCT02420314 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Joseph J. Cullen, MD, FACS |
2015-04 | PHASE2 |
| NCT02617849 | UNKNOWN | Metastatic Malignant Melanoma |
Wilson Miller |
2016-05-19 | PHASE2 |
| NCT04265534 | TERMINATED | Non-Small Cell Lung Cancer; Non-squamous Non-small-cell Lung Cancer; Non-Squamous Non-Small Cell Neoplasm of Lung; KEAP1 Gene Mutation; NRF2 Gene Mutation; NFE2L2 Gene Mutation |
Calithera Biosciences, Inc |
2020-07-24 | PHASE2 |
| NCT02628405 | UNKNOWN | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma |
Academic and Community Cancer Research United |
2016-05-20 | PHASE1; PHASE2 |
| NCT04684017 | UNKNOWN | SCLC; Anlotinib |
Shanghai Chest Hospital |
2019-05-01 | PHASE2 |
| NCT01779050 | TERMINATED | Breast Neoplasms |
Washington University School of Medicine |
2013-12-19 | PHASE2 |
| NCT04108013 | UNKNOWN | Lung Cancer Stage II; PD-1 Antibody; Non-small Cell Lung Cancer |
Xuanwu Hospital, Beijing |
2019-10-08 | PHASE2 |
| NCT03351361 | COMPLETED | Advanced Non Small Cell Lung Cancer |
Rennes University Hospital |
2018-02-19 | PHASE3 |
| NCT04073537 | UNKNOWN | Squamous Non-small Cell Lung Cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-10-31 | PHASE3 |
| NCT02822157 | UNKNOWN | Ovarian Epithelial Cancer |
Universitaire Ziekenhuizen KU Leuven |
2016-08 | PHASE2 |
| NCT03744026 | COMPLETED | Glioblastoma, Adult |
CarThera |
2019-02-18 | PHASE1; PHASE2 |
| NCT04470674 | WITHDRAWN | Lung Cancer; Non-small Cell Lung Cancer; PD-L1 Gene Mutation; KRAS Activating Mutation |
Shirish M Gadgeel |
2021-04-06 | PHASE2 |
| NCT03295552 | TERMINATED | Breast Neoplasm |
Shanghai Jiao Tong University School of Medicine |
2017-11-15 | PHASE2 |
| NCT03987867 | UNKNOWN | Non-small Cell Lung Cancer; First-line Treatment |
Tianjin Medical University Cancer Institute and Hospital |
2019-06-01 | PHASE1 |
| NCT02445391 | ACTIVE_NOT_RECRUITING | Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma |
ECOG-ACRIN Cancer Research Group |
2015-10-20 | PHASE3 |
| NCT03349346 | WITHDRAWN | Diffuse Large B-Cell Lymphoma; Mediastinal B-cell Lymphoma |
Gilead Sciences |
2019-06 | PHASE1 |
| NCT03901378 | WITHDRAWN | Neuroendocrine Carcinoma; Large Cell Neuroendocrine Carcinoma of the Lung; High Grade Neuroendocrine Carcinoma, Any Site |
Ochsner Health System |
2019-10-02 | PHASE2 |
| NCT02862457 | COMPLETED | Neoplasms; Carcinoma, Non-Small-Cell Lung |
Merck Sharp & Dohme LLC |
2016-08-23 | PHASE1 |
| NCT02025881 | TERMINATED | High-risk Medulloblastoma |
Gustave Roussy, Cancer Campus, Grand Paris |
2013-09-14 | PHASE1; PHASE2 |
| NCT03717155 | COMPLETED | Squamous Non-Small Cell Lung Cancer |
Merck KGaA, Darmstadt, Germany |
2018-10-30 | PHASE2 |
| NCT02580994 | COMPLETED | Small Cell Lung Cancer (SCLC) |
European Organisation for Research and Treatment of Cancer - EORTC |
2017-12-08 | PHASE2 |
| NCT03394885 | COMPLETED | Ovarian Cancer; Ovarian Neoplasms |
Duke University |
2018-06-19 | PHASE1; PHASE2 |
| NCT03912402 | UNKNOWN | Cervical Cancer; Cervical Cancer Metastatic; Cervical Cancer Recurrent |
Biocad |
2018-12-25 | PHASE2 |
| NCT01372579 | UNKNOWN | Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer |
Northwestern University |
2011-08 | PHASE2 |
| NCT03117049 | COMPLETED | Non-Small Cell Lung Cancer |
Ono Pharmaceutical Co., Ltd. |
2017-06-13 | PHASE3 |
| NCT03628521 | UNKNOWN | Lung Cancer; Advanced Stage |
Shanghai Chest Hospital |
2018-07-20 | PHASE1 |
| NCT05169801 | COMPLETED | Non-small Cell Lung Cancer(NSCLC) |
Jiangsu HengRui Medicine Co., Ltd. |
2018-01-25 | PHASE3 |
| NCT02177552 | UNKNOWN | Esophageal Neoplasms; Stomach Neoplasms |
Rigshospitalet, Denmark |
2014-06 | PHASE2 |
| NCT00392327 | COMPLETED | Anaplastic Medulloblastoma; Medulloblastoma |
Children's Oncology Group |
2007-05-23 | PHASE3 |
| NCT02044601 | WITHDRAWN | Lung Cancer |
M.D. Anderson Cancer Center |
2014-06 | PHASE1; PHASE2 |
| NCT02116959 | TERMINATED | Advanced Intra-Ocular Retinoblastoma; Retinoblastoma |
University of California, San Francisco |
2014-07-23 | PHASE1 |
| NCT03950674 | COMPLETED | Non-Small-Cell Lung Carcinoma |
Merck Sharp & Dohme LLC |
2016-02-22 | PHASE3 |
| NCT02065687 | UNKNOWN | Endometrial Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Uterine Corpus Cancer AJCC v7; Stage IIIA Uterine Corpus Cancer AJCC v7; Stage IIIB Uterine Corpus Cancer AJCC v7; Stage IIIC Uterine Corpus Cancer AJCC v7; Stage IV Uterine Corpus Cancer AJCC v7; Stage IVA Uterine Corpus Cancer AJCC v7; Stage IVB Uterine Corpus Cancer AJCC v7 |
Gynecologic Oncology Group |
2014-03-17 | PHASE2; PHASE3 |
| NCT02186847 | COMPLETED | Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma; Non-Small Cell Lung Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer |
NRG Oncology |
2014-08 | PHASE2 |
| NCT03058939 | WITHDRAWN | Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III |
University of Chicago |
2018-11 | PHASE2 |
| NCT01966913 | UNKNOWN | Germ Cell Tumor |
Assistance Publique - Hôpitaux de Paris |
2012-04 | PHASE1; PHASE2 |
| NCT03432598 | COMPLETED | Locally Advanced Lung Cancer; Metastatic Lung Cancer |
BeiGene |
2017-08-24 | PHASE2 |
| NCT01490749 | COMPLETED | Esophageal Cancer; Neoplasms, Esophageal |
Emory University |
2012-02 | PHASE1 |
| NCT03151161 | UNKNOWN | Lung, Carcinoma |
Sun Yat-sen University |
2015-12 | PHASE2 |
| NCT02272790 | COMPLETED | Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation |
AstraZeneca |
2015-01-30 | PHASE2 |
| NCT02686346 | COMPLETED | Hodgkin Disease |
The Lymphoma Academic Research Organisation |
2016-03 | PHASE1; PHASE2 |
| NCT02453282 | ACTIVE_NOT_RECRUITING | Non-Small-Cell Lung Carcinoma NSCLC |
AstraZeneca |
2015-07-21 | PHASE3 |
| NCT02744898 | COMPLETED | Endometrial Cancer |
NYU Langone Health |
2016-07 | PHASE2 |
| NCT01367301 | TERMINATED | Stage IA Uterine Sarcoma; Stage IB Uterine Sarcoma; Stage IC Uterine Sarcoma; Stage IIA Uterine Sarcoma; Stage IIB Uterine Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Carcinosarcoma |
Albert Einstein College of Medicine |
2011-07-08 | |
| NCT03574649 | WITHDRAWN | Non Small Cell Lung Cancer |
ImmunityBio, Inc. |
2018-06 | PHASE2 |
| NCT01185171 | COMPLETED | Head and Neck Cancer |
University of Chicago |
2003-01-27 | PHASE2 |
| NCT02253212 | COMPLETED | Glioblastoma; Glioma; Brain Tumor |
Assistance Publique - Hôpitaux de Paris |
2014-07 | PHASE1; PHASE2 |
| NCT02622074 | COMPLETED | Triple Negative Breast Neoplasms |
Merck Sharp & Dohme LLC |
2016-01-27 | PHASE1 |
| NCT02126969 | COMPLETED | Head and Neck Cancer; Larynx |
Susanne Arnold |
2014-10 | PHASE2 |
| NCT02407600 | UNKNOWN | Non-small Cell Lung Cancer; Vomiting; Nausea; Emesis |
Ajeet Gajra |
2015-04 | PHASE2 |
| NCT01376310 | TERMINATED | Cancer |
Novartis Pharmaceuticals |
2010-11-02 | PHASE2 |
| NCT02470468 | COMPLETED | Stage IV Non-small Cell Lung Cancer |
SOTIO a.s. |
2014-12 | PHASE1; PHASE2 |
| NCT00997906 | UNKNOWN | Head and Neck Cancer |
National Cancer Centre, Singapore |
2009-09-15 | PHASE2; PHASE3 |
| NCT00780494 | COMPLETED | Stomach Cancer; Gastric (Stomach) Cancer; Neoplasm of Cardioesophageal Junction; Gastrointestinal Stromal Tumor (GIST) |
Stanford University |
2009-02 | PHASE2 |
| NCT01644955 | COMPLETED | Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Recurrent Adult Brain Tumor |
James Elder |
2012-06-11 | PHASE1 |
| NCT02409355 | TERMINATED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2015-05-07 | PHASE3 |
| NCT02879097 | UNKNOWN | Non-Small Cell Lung Carcinoma |
Cipla BioTec Pvt. Ltd. |
2016-12 | PHASE3 |
| NCT02424045 | COMPLETED | T-cell Lymphoma |
Samsung Medical Center |
2015-05 | PHASE2 |
| NCT02051868 | UNKNOWN | Squamous Cell Carcinoma of the Anus |
Royal Marsden NHS Foundation Trust |
2013-12 | PHASE2 |
| NCT02499770 | COMPLETED | Small Cell Lung Cancer |
G1 Therapeutics, Inc. |
2015-06-26 | PHASE1; PHASE2 |
| NCT01654146 | UNKNOWN | Ovarian Cancer |
Medical Research Council |
2011-06 | PHASE3 |
| NCT01169636 | COMPLETED | Hodgkin's Lymphoma |
M.D. Anderson Cancer Center |
2011-01-31 | PHASE1; PHASE2 |
| NCT02219737 | COMPLETED | CD20 Positive; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma |
National Cancer Institute (NCI) |
2014-09-12 | PHASE1 |
| NCT01701349 | WITHDRAWN | Anaplastic Thyroid Cancer |
Mateon Therapeutics |
2015-03 | PHASE3 |
| NCT01752686 | UNKNOWN | Breast Cancer |
Severance Hospital |
2013-03 | PHASE3 |
| NCT01352962 | COMPLETED | Urethral Neoplasms; Neoplasms, Urethral; Cancer of the Urethra; Urethral Cancer |
National Cancer Institute (NCI) |
2011-09-26 | PHASE1 |
| NCT01041781 | TERMINATED | Lung Cancer |
Alliance for Clinical Trials in Oncology |
2010-02 | PHASE3 |
| NCT02106546 | COMPLETED | Squamous Non-Small Cell Lung Cancer |
AbbVie |
2014-04-10 | PHASE3 |
| NCT02207361 | UNKNOWN | Metastatic Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2013-12 | PHASE4 |
| NCT02207335 | UNKNOWN | Metastatic Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2013-12 | PHASE3 |
| NCT00989651 | COMPLETED | Fallopian Tube Carcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Neoplasm; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Brenner Tumor; Ovarian Carcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Tumor; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7 |
National Cancer Institute (NCI) |
2009-10-28 | PHASE1 |
| NCT01189968 | COMPLETED | Non Small Cell Lung Cancer |
OncoMed Pharmaceuticals, Inc. |
2010-09 | PHASE1 |
| NCT00614822 | COMPLETED | Non Small Cell Lung Cancer |
Christiana Care Health Services |
2007-11 | PHASE2 |
| NCT02161679 | WITHDRAWN | Triple-negative Breast Cancer |
Gilead Sciences |
2016-08 | PHASE2 |
| NCT02319889 | TERMINATED | Stage I Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer |
Case Comprehensive Cancer Center |
2016-02-02 | EARLY_PHASE1 |
| NCT01549093 | UNKNOWN | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2011-08 | PHASE2 |
| NCT01887340 | UNKNOWN | Seminoma |
Gustave Roussy, Cancer Campus, Grand Paris |
2013-06 | PHASE2 |
| NCT00702572 | TERMINATED | Non-small Cell Lung Cancer |
Milton S. Hershey Medical Center |
2008-04 | PHASE1 |
| NCT04031703 | COMPLETED | Breast Cancer |
Fudan University |
2011-01-01 | PHASE3 |
| NCT01493843 | COMPLETED | Non-Small Cell Lung Cancer |
Genentech, Inc. |
2012-01-20 | PHASE2 |
| NCT01256268 | COMPLETED | Endometrial Cancer; Ovarian Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2011-06-13 | PHASE1 |
| NCT01702714 | WITHDRAWN | Non-Squamous Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2014-07 | PHASE1 |
| NCT01280058 | COMPLETED | Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2010-12 | PHASE2 |
| NCT01191892 | COMPLETED | Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer |
Cardiff University |
2010-06 | PHASE2 |
| NCT01704287 | COMPLETED | Malignant Melanoma |
Merck Sharp & Dohme LLC |
2012-11-20 | PHASE2 |
| NCT01496742 | COMPLETED | Non-Squamous Non-Small Cell Lung Cancer |
Genentech, Inc. |
2012-04 | PHASE2 |
| NCT00744718 | COMPLETED | Ovarian Cancer |
Vejle Hospital |
2008-08 | PHASE2 |
| NCT01936974 | TERMINATED | Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma |
Western Regional Medical Center |
2013-09 | PHASE2 |
| NCT01412229 | COMPLETED | Head and Neck Cancer |
UNC Lineberger Comprehensive Cancer Center |
2012-02 | PHASE2 |
| NCT01555710 | UNKNOWN | Extensive-Stage Small Cell Lung Cancer |
Alaunos Therapeutics |
2012-05 | PHASE3 |
| NCT02001896 | UNKNOWN | Non-Small Cell Lung Cancer |
Xinjiang Medical University |
2013-12 | PHASE3 |
| NCT01331525 | COMPLETED | Extensive Stage Small Cell Lung Cancer |
University Hospital Southampton NHS Foundation Trust |
2011-06 | PHASE2 |
| NCT01487915 | UNKNOWN | Advanced Urothelial Carcinoma |
Asan Medical Center |
2010-10 | PHASE2 |
| NCT01450761 | COMPLETED | Small Cell Lung Carcinoma |
Bristol-Myers Squibb |
2011-12-13 | PHASE3 |
| NCT01317615 | COMPLETED | Carcinoma, Large Cell; Neuroendocrine Tumors |
Novartis Pharmaceuticals |
2011-04 | PHASE4 |
| NCT01815242 | COMPLETED | Breast Cancer |
Women's Cancer Study Group GmbH |
2013-06 | PHASE2 |
| NCT00749723 | COMPLETED | Recurrent Brain Tumors; Supratentorial PNETs; Medulloblastomas; Ependymomas |
University Hospital, Bonn |
2006-02-01 | PHASE2; PHASE3 |
| NCT01683682 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Aktion Bronchialkarzinom e.V. |
2013-04 | PHASE1 |
| NCT00704639 | COMPLETED | Head and Neck Cancer |
Trans Tasman Radiation Oncology Group |
2008-04 | PHASE1; PHASE2 |
| NCT01781988 | COMPLETED | Lung Cancer; Carboplatin Adverse Reaction |
Guangzhou Medical University |
2009-06 | PHASE2 |
| NCT00021255 | COMPLETED | Breast Neoplasms |
Sanofi |
2001-04 | PHASE3 |
| NCT00690872 | UNKNOWN | Head and Neck Cancer |
National Cancer Centre, Singapore |
2008-07 | PHASE2 |
| NCT01309607 | UNKNOWN | ErbB2-Positive Stage I-III Breast Cancer |
National University Hospital, Singapore |
2011-04 | PHASE2 |
| NCT01688791 | TERMINATED | Advanced Cancer |
Endocyte |
2012-12 | PHASE1 |
| NCT00861705 | COMPLETED | Male Breast Carcinoma; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2009-07-21 | PHASE2 |
| NCT00953420 | COMPLETED | Nasopharyngeal Carcinoma |
Baylor College of Medicine |
2009-11 | PHASE2 |
| NCT01275664 | TERMINATED | Nausea and Vomiting; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Cystadenocarcinoma; Stage II Ovarian Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Undifferentiated Ovarian Carcinoma |
Gynecologic Oncology Group |
2011-06 | |
| NCT01570582 | UNKNOWN | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer |
Korean Gynecologic Oncology Group |
2010-03 | PHASE2 |
| NCT00317408 | UNKNOWN | Lymphoma |
European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma |
2004-04 | |
| NCT00648648 | COMPLETED | Solid Tumors |
Merck Sharp & Dohme LLC |
2008-02-25 | PHASE1 |
| NCT01463501 | UNKNOWN | Esophageal Cancer |
Zhejiang Cancer Hospital |
2011-10 | PHASE2 |
| NCT01004172 | COMPLETED | Metastatic Breast Cancer; Breast Cancer; Progressive Breast Cancer |
Dana-Farber Cancer Institute |
2009-11 | PHASE2 |
| NCT01236716 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Chinese Society of Lung Cancer |
2010-11 | PHASE2 |
| NCT00321334 | COMPLETED | Non-small Cell Lung Cancer |
Chinese Society of Lung Cancer |
2006-03 | PHASE3 |
| NCT00769470 | COMPLETED | Breast Cancer |
Translational Oncology Research International |
2009-04 | PHASE2 |
| NCT01293630 | COMPLETED | Advanced Solid Tumors |
Sanofi |
2011-01 | PHASE1 |
| NCT01268059 | TERMINATED | Non-small Cell Lung Cancer |
MedImmune LLC |
2010-12-16 | PHASE1; PHASE2 |
| NCT01200342 | TERMINATED | Melanoma |
M.D. Anderson Cancer Center |
2010-12 | PHASE2 |
| NCT00998192 | COMPLETED | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung |
Oncolytics Biotech |
2009-10 | PHASE2 |
| NCT01617928 | COMPLETED | Solid Tumors |
AbbVie (prior sponsor, Abbott) |
2012-05 | PHASE1 |
| NCT00887575 | COMPLETED | Breast Cancer |
SCRI Development Innovations, LLC |
2009-06 | PHASE1; PHASE2 |
| NCT00621049 | COMPLETED | Non-Small Cell Lung Cancer |
SCRI Development Innovations, LLC |
2007-12 | PHASE2 |
| NCT01038037 | TERMINATED | Non Small Cell Lung Cancer |
Vejle Hospital |
2010-01 | PHASE2 |
| NCT00147225 | COMPLETED | Solid Tumors; Advanced Cancer |
M.D. Anderson Cancer Center |
2005-08 | PHASE1; PHASE2 |
| NCT01366131 | COMPLETED | Non-Squamous Non-Small Cell Lung Cancer |
Genentech, Inc. |
2011-06 | PHASE2 |
| NCT01542047 | TERMINATED | Cancer, Metastatic |
New Mexico Cancer Research Alliance |
2012-08 | PHASE1 |
| NCT00927589 | COMPLETED | Solid Cancers |
Genentech, Inc. |
2009-07 | PHASE1 |
| NCT00948675 | COMPLETED | Advanced Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2009-09-01 | PHASE3 |
| NCT01364012 | COMPLETED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2011-05-23 | PHASE3 |
| NCT00949247 | COMPLETED | Breast Cancer |
Case Comprehensive Cancer Center |
2009-12 | EARLY_PHASE1 |
| NCT01527864 | UNKNOWN | Non Small Cell Lung Cancer |
Beijing Protgen Biotechnology Development Co., Ltd. |
2011-05 | PHASE2 |
| NCT01531790 | COMPLETED | Non-Small Cell Lung Cancer |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2011-09 | PHASE1 |
| NCT01242072 | UNKNOWN | Malignancy; Cancer; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Testicular Cancer; Thymoma; Ovarian Cancer; Osteosarcoma |
Alaunos Therapeutics |
2010-11 | PHASE1 |
| NCT01229930 | COMPLETED | Cervical Cancer |
University of Glasgow |
2010-06 | PHASE2 |
| NCT01038752 | TERMINATED | Non-small Cell Lung Cancer |
Optimum Therapeutics, LLC |
2010-08 | PHASE2 |
| NCT00960297 | TERMINATED | Non-Small Cell Lung Cancer |
SCRI Development Innovations, LLC |
2009-08 | PHASE2 |
| NCT01234038 | COMPLETED | Non-small Cell Lung Cancer |
Ionis Pharmaceuticals, Inc. |
2010-11 | PHASE1; PHASE2 |
| NCT00700180 | COMPLETED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2008-09 | PHASE2 |
| NCT00927875 | COMPLETED | Small Cell Lung Carcinoma |
Bristol-Myers Squibb |
2010-02 | PHASE1 |
| NCT00255723 | COMPLETED | Lymphoma |
Memorial Sloan Kettering Cancer Center |
2004-04 | PHASE2 |
| NCT01313663 | TERMINATED | Lung Cancer, Small Cell |
GlaxoSmithKline |
2011-02 | PHASE2 |
| NCT00439361 | COMPLETED | Hodgkin Lymphoma; Lymphoma |
M.D. Anderson Cancer Center |
2007-02 | PHASE1 |
| NCT00976183 | TERMINATED | Ovarian Neoplasms |
Gynecologic Oncology Associates |
2009-10 | PHASE1; PHASE2 |
| NCT01151761 | TERMINATED | Cholangiocarcinoma; Hepatobiliary Neoplasm; Liver Cancer; Bile Duct Cancer; Cancer of Gallbladder |
Stanford University |
2011-01 | PHASE2 |
| NCT00588666 | COMPLETED | Myeloproliferative Disorder; Urothelial Carcinoma; Cancer |
Memorial Sloan Kettering Cancer Center |
2006-05 | PHASE2 |
| NCT00281515 | COMPLETED | Epithelial Ovarian Cancer |
AGO Study Group |
2006-01 | PHASE2 |
| NCT00515138 | TERMINATED | Lymphoma, B-Cell |
University of California, San Francisco |
2007-05 | EARLY_PHASE1 |
| NCT00735696 | COMPLETED | Non Small Cell Lung Cancer |
Eli Lilly and Company |
2009-01 | PHASE2 |
| NCT01012336 | COMPLETED | Chemotherapy-Induced Nausea and Vomiting; Ovarian Cancer |
Samsung Medical Center |
2010-05 | PHASE2 |
| NCT00482014 | COMPLETED | Non-Small-Cell Lung Cancer |
Eli Lilly and Company |
2007-05 | PHASE1; PHASE2 |
| NCT00550537 | COMPLETED | Lung Cancer |
Vanderbilt-Ingram Cancer Center |
2007-10 | PHASE2 |
| NCT00352495 | COMPLETED | Brain and Central Nervous System Tumors; Neurofibromatosis Type 1 |
Children's Oncology Group |
2006-06 | PHASE1 |
| NCT00301028 | COMPLETED | Head and Neck Cancer |
M.D. Anderson Cancer Center |
2006-04 | PHASE2 |
| NCT00821886 | COMPLETED | Breast Cancer |
SCRI Development Innovations, LLC |
2009-02 | PHASE2 |
| NCT00231868 | COMPLETED | Uterine Cancer |
Montefiore Medical Center |
2001-12 | PHASE2 |
| NCT00958022 | TERMINATED | Small Cell Lung Cancer |
Ahmad Tarhini |
2009-09 | PHASE1 |
| NCT00848718 | COMPLETED | Locally Advanced, Metastatic Solid Tumors |
Merck Sharp & Dohme LLC |
2009-03-17 | PHASE1 |
| NCT01057342 | COMPLETED | Lung Cancer |
Swiss Cancer Institute |
2010-01 | PHASE2 |
| NCT00334321 | COMPLETED | Endometrial Cancer |
Washington University School of Medicine |
2006-04 | PHASE1 |
| NCT00256243 | COMPLETED | Breast Cancer |
Rita Sanghvi, Mehta |
2004-04 | PHASE2 |
| NCT00938652 | COMPLETED | Breast Cancer |
Sanofi |
2009-07 | PHASE3 |
| NCT00687297 | COMPLETED | Lung Cancer; Non Small Cell Lung Cancer |
PrECOG, LLC. |
2008-04 | PHASE2 |
| NCT00392886 | UNKNOWN | Brain and Central Nervous System Tumors |
Children's Hospital Los Angeles |
2004-03 | PHASE3 |
| NCT00820872 | COMPLETED | Breast Cancer |
Alliance for Clinical Trials in Oncology |
2009-02 | PHASE2 |
| NCT01240642 | TERMINATED | Metastatic Cancer With Impaired Renal Function; Metastatic Cancer With Normal Renal Function |
Novartis Pharmaceuticals |
2010-01 | PHASE1 |
| NCT01100359 | UNKNOWN | Endometrial Cancer |
Medical University Innsbruck |
2007-11 | PHASE2 |
| NCT00741988 | COMPLETED | Non-Small Cell Lung Cancer |
SCRI Development Innovations, LLC |
2008-09 | PHASE2 |
| NCT00584909 | TERMINATED | Uterine Cancer |
University of Alabama at Birmingham |
2006-03 | PHASE2 |
| NCT00807612 | TERMINATED | Advanced Squamous Non-Small Cell Lung Cancer |
NantCell, Inc. |
2009-01 | PHASE1; PHASE2 |
| NCT00426582 | COMPLETED | Advanced Solid Tumors |
Novartis Pharmaceuticals |
2006-08 | PHASE1 |
| NCT00919880 | COMPLETED | Breast Cancer |
Tao OUYANG |
2009-07 | PHASE2 |
| NCT00520676 | COMPLETED | Non-Small Cell Lung Cancer |
Eli Lilly and Company |
2007-10 | PHASE3 |
| NCT00687817 | COMPLETED | Non-small Cell Lung Cancer |
Peregrine Pharmaceuticals |
2008-06 | PHASE2 |
| NCT00601718 | COMPLETED | Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Waldenström Macroglobulinemia |
University of Washington |
2007-12 | PHASE1; PHASE2 |
| NCT00456261 | COMPLETED | Lung Cancer |
SCRI Development Innovations, LLC |
2007-03 | PHASE2 |
| NCT00489359 | COMPLETED | Ovarian Cancer; Primary Peritoneal Cancer |
Eli Lilly and Company |
2005-07 | PHASE1; PHASE2 |
| NCT00496028 | COMPLETED | Neoplasms |
AstraZeneca |
2007-03 | PHASE1 |
| NCT00457119 | COMPLETED | Non Small Cell Lung Cancer |
Novartis Pharmaceuticals |
2007-02 | PHASE1 |
| NCT00540514 | COMPLETED | Non-Small Cell Lung Carcinoma |
Celgene |
2007-11-01 | PHASE3 |
| NCT00215930 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
H. Lee Moffitt Cancer Center and Research Institute |
2004-02 | PHASE2 |
| NCT00708812 | COMPLETED | Advanced Non-small Cell Lung Cancer |
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd |
2007-07 | PHASE2 |
| NCT00101283 | COMPLETED | Mesothelioma |
Eastern Cooperative Oncology Group |
2006-02-23 | PHASE2 |
| NCT00610714 | COMPLETED | Ovarian Neoplasms; Ovarian Cancer |
AstraZeneca |
2008-04 | PHASE2 |
| NCT00354549 | COMPLETED | Lung Cancer |
Swiss Cancer Institute |
2006-01 | PHASE2 |
| NCT00434252 | COMPLETED | Melanoma |
Genentech, Inc. |
2007-02 | PHASE2 |
| NCT00508625 | COMPLETED | Non-Small Cell Lung Cancer |
Amgen |
2006-06 | PHASE2 |
| NCT00113516 | COMPLETED | Non-small Cell Lung Cancer |
Pfizer |
2005-09 | PHASE2 |
| NCT00316186 | COMPLETED | Lung Cancer, Small Cell |
GlaxoSmithKline |
2005-06 | PHASE2 |
| NCT00562185 | WITHDRAWN | Ovarian Cancer |
University of Texas Southwestern Medical Center |
2008-05 | PHASE1; PHASE2 |
| NCT00004074 | COMPLETED | Advanced Adult Primary Liver Cancer; Anaplastic Thyroid Cancer; Bone Metastases; Carcinoma of the Appendix; Distal Urethral Cancer; Fallopian Tube Cancer; Gastrinoma; Glucagonoma; Inflammatory Breast Cancer; Insulinoma; Liver Metastases; Localized Unresectable Adult Primary Liver Cancer; Lung Metastases; Male Breast Cancer; Malignant Pericardial Effusion; Malignant Pleural Effusion; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Parathyroid Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Newly Diagnosed Carcinoma of Unknown Primary; Occult Non-small Cell Lung Cancer; Pancreatic Polypeptide Tumor; Primary Peritoneal Cavity Cancer; Proximal Urethral Cancer; Pulmonary Carcinoid Tumor; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Adrenocortical Carcinoma; Recurrent Adult Primary Liver Cancer; Recurrent Anal Cancer; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Carcinoma of Unknown Primary; Recurrent Cervical Cancer; Recurrent Colon Cancer; Recurrent Endometrial Carcinoma; Recurrent Esophageal Cancer; Recurrent Extrahepatic Bile Duct Cancer; Recurrent Gallbladder Cancer; Recurrent Gastric Cancer; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Pancreatic Cancer; Recurrent Parathyroid Cancer; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Salivary Gland Cancer; Recurrent Small Intestine Cancer; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Thyroid Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Recurrent Vaginal Cancer; Recurrent Vulvar Cancer; Skin Metastases; Small Intestine Adenocarcinoma; Somatostatinoma; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Adrenocortical Carcinoma; Stage III Bladder Cancer; Stage III Cervical Cancer; Stage III Colon Cancer; Stage III Endometrial Carcinoma; Stage III Esophageal Cancer; Stage III Follicular Thyroid Cancer; Stage III Gastric Cancer; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Ovarian Epithelial Cancer; Stage III Pancreatic Cancer; Stage III Papillary Thyroid Cancer; Stage III Prostate Cancer; Stage III Rectal Cancer; Stage III Renal Cell Cancer; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Vaginal Cancer; Stage III Vulvar Cancer; Stage IIIA Anal Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Anal Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Adenoid Cystic Carcinoma of the Oral Cavity; Stage IV Adrenocortical Carcinoma; Stage IV Anal Cancer; Stage IV Bladder Cancer; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Endometrial Carcinoma; Stage IV Esophageal Cancer; Stage IV Follicular Thyroid Cancer; Stage IV Gastric Cancer; Stage IV Mucoepidermoid Carcinoma of the Oral Cavity; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Pancreatic Cancer; Stage IV Papillary Thyroid Cancer; Stage IV Prostate Cancer; Stage IV Rectal Cancer; Stage IV Renal Cell Cancer; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IVA Cervical Cancer; Stage IVA Vaginal Cancer; Stage IVB Cervical Cancer; Stage IVB Vaginal Cancer; Stage IVB Vulvar Cancer; Thyroid Gland Medullary Carcinoma; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer; Urethral Cancer Associated With Invasive Bladder Cancer; WDHA Syndrome |
National Cancer Institute (NCI) |
1999-08 | PHASE1 |
| NCT00511849 | COMPLETED | Neoplasms |
Pfizer |
2005-11 | PHASE1 |
| NCT00060359 | COMPLETED | Fallopian Tube Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Undifferentiated Ovarian Carcinoma |
Gynecologic Oncology Group |
2003-04 | PHASE1 |
| NCT00189553 | COMPLETED | Ovarian Cancer; Fallopian Tube Cancer |
ARCAGY/ GINECO GROUP |
2005-04 | PHASE3 |
| NCT00470249 | TERMINATED | Breast Cancer |
University of Southampton |
2006-07-15 | PHASE2 |
| NCT00498953 | COMPLETED | Head and Neck Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2007-05 | PHASE1; PHASE2 |
| NCT00191451 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2004-04 | PHASE2 |
| NCT00666692 | COMPLETED | Non-small Cell Lung Cancer |
Abbott |
2008-04 | PHASE1 |
| NCT02004093 | COMPLETED | Ovarian Cancer |
Hoffmann-La Roche |
2005-12 | PHASE2 |
| NCT00606125 | COMPLETED | Neoplasms |
Bayer |
2007-05 | PHASE1 |
| NCT00369070 | TERMINATED | Advanced Non-squamous NSCLC |
Amgen |
2007-01-31 | PHASE2 |
| NCT00561795 | COMPLETED | Primary Peritoneal Carcinoma; Tumor; Epithelial Ovarian Cancer; Uterine Disease; Cervix Diseases; Neoplasms, Ovarian; Cancer |
GlaxoSmithKline |
2007-09 | PHASE2 |
| NCT00158379 | COMPLETED | Ovarian Cancer |
North Eastern German Society of Gynaecological Oncology |
2003-07 | PHASE2 |
| NCT00094861 | COMPLETED | Dysphagia; Non-Small Cell Lung Cancer; Lung Cancer |
Swedish Orphan Biovitrum |
2005-01 | PHASE2 |
| NCT00401609 | COMPLETED | Small Cell Lung Cancer |
National Cancer Institute, Naples |
2000-11 | PHASE1; PHASE2 |
| NCT00004188 | COMPLETED | Neuroblastoma |
Children's Oncology Group |
2001-02 | PHASE3 |
| NCT00258739 | COMPLETED | Lung Neoplasms |
Sanofi |
2001-10 | PHASE2 |
| NCT01124435 | COMPLETED | Ovarian Neoplasms |
Catholic University of the Sacred Heart |
2003-10 | PHASE2 |
| NCT00085501 | COMPLETED | Lung Cancer |
SWOG Cancer Research Network |
2004-07 | PHASE2 |
| NCT00281788 | COMPLETED | Esophageal Cancer |
Duke University |
2003-09 | PHASE1 |
| NCT00075751 | COMPLETED | Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2004-01 | PHASE2 |
| NCT01172470 | COMPLETED | Head and Neck Cancer |
University of Chicago |
2005-06 | PHASE2 |
| NCT00387374 | COMPLETED | Adenosquamous Cell Lung Cancer; Drug/Agent Toxicity by Tissue/Organ; Hemoptysis; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2006-10 | PHASE2 |
| NCT00308529 | COMPLETED | Carcinoma, Small Cell Lung; Lung Cancer |
SCRI Development Innovations, LLC |
2006-03 | PHASE2 |
| NCT00085839 | COMPLETED | Non-Small Cell Lung Cancer |
OSI Pharmaceuticals |
2004-02 | PHASE2 |
| NCT00014118 | COMPLETED | Head and Neck Cancer |
Eastern Cooperative Oncology Group |
2001-06-06 | PHASE2 |
| NCT00094835 | COMPLETED | Lung Cancer; Non-Small Cell Lung Cancer |
Amgen |
2005-01 | PHASE1; PHASE2 |
| NCT00113438 | COMPLETED | Cancer; Tumor |
Mateon Therapeutics |
2005-03 | PHASE2 |
| NCT00061919 | COMPLETED | Lung Cancer |
University College, London |
2003-04 | PHASE3 |
| NCT00660140 | COMPLETED | Cholangiocarcinoma; Gallbladder Cancer |
Washington University School of Medicine |
2002-03 | PHASE2 |
| NCT00005976 | COMPLETED | Brain and Central Nervous System Tumors |
National Cancer Institute (NCI) |
2000-05 | PHASE2 |
| NCT00255762 | COMPLETED | Recurrent Melanoma; Stage IV Melanoma |
National Cancer Institute (NCI) |
2005-12 | PHASE2 |
| NCT00062062 | COMPLETED | Lung Cancer |
Alliance for Clinical Trials in Oncology |
2004-10 | PHASE2 |
| NCT00161278 | TERMINATED | Advanced Non-Small Cell Lung Cancer |
University of Michigan Rogel Cancer Center |
2004-12 | PHASE2 |
| NCT00086944 | COMPLETED | Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma |
National Cancer Institute (NCI) |
2004-05 | PHASE1; PHASE2 |
| NCT00055835 | COMPLETED | Bladder Cancer; Urethral Cancer |
SWOG Cancer Research Network |
2002-11 | PHASE2 |
| NCT00006235 | COMPLETED | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Gynecologic Oncology Group |
PHASE1 | |
| NCT00280787 | COMPLETED | Non Small Cell Lung Cancer |
UNC Lineberger Comprehensive Cancer Center |
2003-11 | PHASE2 |
| NCT00047255 | COMPLETED | Breast Cancer |
Jonsson Comprehensive Cancer Center |
2002-05 | PHASE3 |
| NCT00136175 | COMPLETED | Bladder Cancer |
University of Michigan Rogel Cancer Center |
1999-11 | PHASE2 |
| NCT00193362 | COMPLETED | Lung Cancer |
SCRI Development Innovations, LLC |
2004-06 | PHASE3 |
| NCT00042978 | COMPLETED | Extensive Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer |
National Cancer Institute (NCI) |
2003-04 | PHASE2 |
| NCT00007813 | COMPLETED | Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ovarian Cancer; Sarcoma; Testicular Germ Cell Tumor |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
1997-05-31 | PHASE1 |
| NCT00052338 | COMPLETED | Malignant Pleural Effusion; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2002-09 | PHASE1 |
| NCT00003864 | COMPLETED | Esophageal Cancer |
Eastern Cooperative Oncology Group |
1999-09-03 | PHASE2 |
| NCT00005810 | COMPLETED | Prostate Cancer |
Alliance for Clinical Trials in Oncology |
2000-03 | PHASE2 |
| NCT00002943 | COMPLETED | Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific |
Wake Forest University Health Sciences |
1993-02 | PHASE2 |
| NCT00042302 | TERMINATED | Stage IIIb Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
QLT Inc. |
2002-06 | PHASE3 |
| NCT00170664 | COMPLETED | Ovarian Cancer |
North Eastern German Society of Gynaecological Oncology |
1999-01 | PHASE2 |
| NCT00017407 | COMPLETED | Lung Cancer |
Ionis Pharmaceuticals, Inc. |
2000-10-13 | PHASE3 |
| NCT00652691 | COMPLETED | Ovarian Cancer; Peritoneal Cavity Cancer |
Mayo Clinic |
1998-08 | PHASE1 |
| NCT00005593 | COMPLETED | Leukemia; Myelodysplastic Syndromes |
Case Comprehensive Cancer Center |
1998-09 | PHASE1 |
| NCT00003587 | COMPLETED | Lung Cancer |
SWOG Cancer Research Network |
1998-10 | PHASE2 |
| NCT00003378 | TERMINATED | Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Gynecologic Oncology Group |
1998-08 | PHASE1 |
| NCT00025610 | COMPLETED | Neuroblastoma |
European Infant Neuroblastoma Study Group - 1999 |
1999-07 | PHASE2 |
| NCT00003912 | COMPLETED | Liver Cancer |
Societe Internationale d'Oncologie Pediatrique |
1998-06 | PHASE3 |
| NCT00074854 | COMPLETED | Lung Neoplasms |
Pfizer |
2002-05 | PHASE1; PHASE2 |
| NCT00088088 | COMPLETED | Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer |
Synta Pharmaceuticals Corp. |
2004-03 | PHASE1; PHASE2 |
| NCT00340184 | COMPLETED | Cervical Cancer |
Korean Gynecologic Oncology Group |
2004-08 | PHASE2 |
| NCT00006049 | UNKNOWN | Lung Cancer |
AstraZeneca |
2000-05 | PHASE3 |
| NCT00005024 | UNKNOWN | Unspecified Adult Solid Tumor, Protocol Specific |
Jonsson Comprehensive Cancer Center |
PHASE3 | |
| NCT00003089 | COMPLETED | Drug/Agent Toxicity by Tissue/Organ; Lung Cancer |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
1997-07 | PHASE2 |
| NCT00030719 | UNKNOWN | Neuroblastoma |
University of Leicester |
2001-12 | PHASE3 |
| NCT00004900 | COMPLETED | Breast Cancer |
Hackensack Meridian Health |
1999-10 | PHASE2 |
| NCT00025623 | COMPLETED | Neuroblastoma |
European Infant Neuroblastoma Study Group - 1999 |
1999-07 | PHASE2 |
| NCT00417053 | UNKNOWN | Neuroblastoma |
Children's Cancer and Leukaemia Group |
PHASE3 | |
| NCT00563160 | UNKNOWN | Lung Neoplasms |
Hospital Authority, Hong Kong |
2005-05 | PHASE2 |
| NCT00736814 | UNKNOWN | Lung Cancer |
Yonsei University |
2008-06 | PHASE2 |
| NCT00365755 | COMPLETED | Neuroblastoma |
Children's Cancer and Leukaemia Group |
PHASE3 | |
| NCT00046995 | UNKNOWN | Colorectal Cancer |
Groupe Regional d'Etudes du Cancer Colorectal |
2001-05 | PHASE3 |
| NCT00189566 | COMPLETED | Ovarian Cancer; Fallopian Tube Cancer; Malignant Tumor of Peritoneum |
ARCAGY/ GINECO GROUP |
2004-04 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-05-15)
Check the
Carboplatin
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Carboplatin Mechanism of Action: PD-1 Inhibition in T Cell Research
- Carboplatin Working Concentration | Cell Culture | Treatment
- Carboplatin Solubility in DMSO
- Carboplatin Storage
- Carboplatin Stability
- Carboplatin Combination Database
- Carboplatin Molecular Weight
- Carboplatin SMILES
- Carboplatin CAS Number
- Carboplatin Chemical Structure (2D and 3D)
- Carboplatin IC50 for Cell-based and Cell-free Assays
- Carboplatin MedChemExpress (HY-17393)? Try a better option.
- Carboplatin Sigma (C2538)? Try a better option.
- Carboplatin Cayman (13112)? Try a better option.
- Carboplatin Abmole (M2288)? Try a better option.
- Carboplatin Tocris (2626)? Try a better option.
- Carboplatin SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.